5 High Growth Stocks to Buy and Hold for the Next Decade

4. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

On May 21, 2026, Bernstein analyst Jeffrey Walch initiated coverage of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) with an Outperform rating and a $221 price target. Walch said Neurocrine is one of the more promising investments within Bernstein’s initial coverage group of mid-cap biopharmaceutical companies, noting that the company’s two key medicines are already approved and have a long runway until loss-of-exclusivity. Bernstein added that upside exists to the current share price as the market gains more certainty around future market share and a potential positive Phase 3 trial readout.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced new data from a clinician survey on patients with mild tardive dyskinesia, or TD, and treatment with INGREZZA, or valbenazine, capsules in a real-world setting. In a subgroup analysis, nearly all patients with clinician-reported mild TD treated with INGREZZA had fewer uncontrolled movements, with most showing symptom improvement within four weeks. The findings were presented at the American Psychiatric Association 2026 Annual Meeting, held May 16-20 in San Francisco. The analysis was based on clinician survey data covering TD symptoms, functional impairment, and improvement after INGREZZA treatment. Before treatment, clinicians reported that mild TD movements affected functional status in 90% of patients and independence in 84% of patients. After INGREZZA was started, 86% of patients with improved uncontrolled movements showed improvement in four weeks or less. Clinicians also reported improvement in more than 90% of impacted patients across functional areas, including speech, dexterity, social status, emotional status, and activities of daily living.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) discovers, develops, and commercializes pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.